
ATRC
AtriCure Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
31.570
Open
30.450
VWAP
31.10
Vol
589.27K
Mkt Cap
1.56B
Low
30.410
Amount
18.33M
EV/EBITDA(TTM)
--
Total Shares
48.38M
EV
1.53B
EV/OCF(TTM)
68.92
P/S(TTM)
3.09
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
139.62M
+12.35%
-0.060
-24.5%
129.58M
+11.79%
-0.146
-14.14%
130.26M
+12.03%
-0.163
-4.31%
Estimates Revision
The market is revising No Change the revenue expectations for AtriCure, Inc. (ATRC) for FY2025, with the revenue forecasts being adjusted by -0% over the past three months. During the same period, the stock price has changed by -6.44%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-10.63%
In Past 3 Month
Stock Price
Go Down

-6.44%
In Past 3 Month
8 Analyst Rating

59.94% Upside
Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 50.38 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy

59.94% Upside
Current: 31.500

Low
40.00
Averages
50.38
High
60.00

59.94% Upside
Current: 31.500

Low
40.00
Averages
50.38
High
60.00
Citizens Capital Markets
Daniel Stauder
Buy
Reiterates
$60
2025-04-02
Reason
Citizens Capital Markets
Daniel Stauder
Price Target
$60
2025-04-02
Reiterates
Buy
Reason
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$66 → $52
2025-03-28
Reason
Canaccord Genuity
William Plovanic
Price Target
$66 → $52
2025-03-28
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on AtriCure to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model folloing the company's Investor Day that both reiterated its 2025 guidance and provided an aspirational LRP that included three-year objectives as well as targets for 2030.
Needham
Mike Matson
Strong Buy
Reiterates
$51
2025-03-27
Reason
Needham
Mike Matson
Price Target
$51
2025-03-27
Reiterates
Strong Buy
Reason
JP Morgan
Lilia-Celine Lozada
Buy
Maintains
$51 → $46
2025-03-27
Reason
JP Morgan
Lilia-Celine Lozada
Price Target
$51 → $46
2025-03-27
Maintains
Buy
Reason
Needham
Mike Matson
Strong Buy
Reiterates
$51
2025-03-21
Reason
Needham
Mike Matson
Price Target
$51
2025-03-21
Reiterates
Strong Buy
Reason
Oppenheimer
Suraj Kalia
Buy
Maintains
$36 → $45
2025-02-13
Reason
Oppenheimer
Suraj Kalia
Price Target
$36 → $45
2025-02-13
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for AtriCure Inc (ATRC.O) is -58.70, compared to its 5-year average forward P/E of -49.89. For a more detailed relative valuation and DCF analysis to assess AtriCure Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-49.89
Current PE
-58.70
Overvalued PE
-37.42
Undervalued PE
-62.36
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
1172.58
Current EV/EBITDA
32.64
Overvalued EV/EBITDA
8466.05
Undervalued EV/EBITDA
-6120.89
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
6.25
Current PS
2.83
Overvalued PS
9.47
Undervalued PS
3.04
Financials
Annual
Quarterly
FY2025Q1
YoY :
+13.57%
123.62M
Total Revenue
FY2025Q1
YoY :
-45.46%
-5.95M
Operating Profit
FY2025Q1
YoY :
-49.15%
-6.75M
Net Income after Tax
FY2025Q1
YoY :
-50.00%
-0.14
EPS - Diluted
FY2025Q1
YoY :
-44.49%
-13.21M
Free Cash Flow
FY2025Q1
YoY :
+0.36%
74.93
Gross Profit Margin - %
FY2025Q1
YoY :
-98.94%
-0.14
FCF Margin - %
FY2025Q1
YoY :
-55.21%
-5.46
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
83.6K
USD
1
3-6
Months
232.5K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
84.3K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
207.4K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
16.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
83.6K
USD
1
3-6
Months
232.5K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
84.3K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ATRC News & Events
Events Timeline
2025-04-29 (ET)
2025-04-29
16:05:26
AtriCure sees FY25 revenue $517M-$527M, consensus $522.85M

2025-04-29
16:04:40
AtriCure reports Q1 adjusted EPS (14c), consensus (22c)

2025-03-26 (ET)
2025-03-26
13:10:05
AtriCure sees 2028 revenue $750M+, adjusted EBITDA margin 14%

Sign Up For More Events
Sign Up For More Events
News
9.0
07-15NewsfilterAtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
8.0
06-30NASDAQ.COMInteresting ATRC Put And Call Options For August 15th
4.0
04-30BenzingaVisa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Sign Up For More News
People Also Watch

IQ
iQIYI Inc
2.000
USD
-1.96%

DAN
Dana Inc
16.270
USD
-0.49%

CABO
Cable One Inc
144.330
USD
-5.52%

CNXN
PC Connection Inc
64.000
USD
-1.33%

LZB
La-Z-Boy Inc
38.390
USD
+1.05%

GRFS
Grifols SA
10.100
USD
+1.61%

HPK
Highpeak Energy Inc
9.400
USD
0.00%

LC
LendingClub Corp
12.830
USD
-2.58%

CASH
Pathward Financial Inc
80.200
USD
+0.06%

SPT
Sprout Social Inc
18.930
USD
-0.73%
FAQ

What is AtriCure Inc (ATRC) stock price today?
The current price of ATRC is 31.5 USD — it has increased 4.41 % in the last trading day.

What is AtriCure Inc (ATRC)'s business?

What is the price predicton of ATRC Stock?

What is AtriCure Inc (ATRC)'s revenue for the last quarter?

What is AtriCure Inc (ATRC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for AtriCure Inc (ATRC)'s fundamentals?

How many employees does AtriCure Inc (ATRC). have?
